EJNMMI Radiopharmacy and Chemistry

metrics 2024

Connecting researchers to inspire breakthroughs in radiopharmacy.

Introduction

EJNMMI Radiopharmacy and Chemistry, published by SpringerNature, stands at the forefront of research in the critical fields of radiopharmacy and nuclear medicine. With an impressive impact factor and a dedicated Open Access policy since 2016, this journal invites the global scientific community to share advancements in the synthesis, development, and application of radiopharmaceuticals within the realm of analytical chemistry and pharmacology. As evidenced by its notable categorizations, including Q1 in Analytical Chemistry and Radiology, Nuclear Medicine and Imaging, along with high Scopus rankings, EJNMMI offers a prestigious platform for rigorous peer-reviewed research that informs and inspires progress in medical imaging and therapeutics. The journal's commitment to accessibility fosters collaboration and innovation, making it an essential resource for researchers, medical professionals, and students seeking to advance their understanding and application of radiopharmaceuticals.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor4.40
Journal Impact Factor (5 years)4.70
H-Index-
Journal IF Without Self4.40
Eigen Factor0.00
Normal Eigen Factor0.26
Influence1.05
Immediacy Index0.40
Cited Half Life3.50
Citing Half Life6.50
JCI1.13
Total Documents-
WOS Total Citations755
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

CHEMISTRY, INORGANIC & NUCLEAR
Rank 6/44
Percentile 87.50
Quartile Q1
CHEMISTRY, MEDICINAL
Rank 19/72
Percentile 74.30
Quartile Q2
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Rank 27/204
Percentile 87.00
Quartile Q1

JCI (Web Of Science)

CHEMISTRY, INORGANIC & NUCLEAR
Rank 6/44
Percentile 86.36
Quartile Q1
CHEMISTRY, MEDICINAL
Rank 16/72
Percentile 77.78
Quartile Q1
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Rank 33/204
Percentile 83.82
Quartile Q1

Quartile History

Similar Journals

EUROPEAN JOURNAL OF RADIOLOGY

Innovating Radiology for a Healthier Future
Publisher: ELSEVIER IRELAND LTDISSN: 0720-048XFrequency: 12 issues/year

The European Journal of Radiology, published by Elsevier Ireland Ltd, is a premier peer-reviewed journal in the fields of radiology, nuclear medicine, and imaging. Established in 1981, it has carved a significant niche within the academic community, showcasing innovative research that enhances medical imaging practices and improves patient care. With an impressive ranking in the Q1 category for both Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging in 2023, the journal is recognized globally for its commitment to advancing scientific knowledge and improving imaging methodologies. The journal's Scopus ranking of #60/333, placing it in the 82nd percentile, underlines its reputation for high-quality research and scholarly contributions. While traditionally a subscription-based journal, it continually evolves to meet the demands of the academic landscape, aiming to bridge the gap between research and clinical practice. Researchers, healthcare professionals, and students alike can benefit from exploring its extensive archives and current publications, which are curated to foster education and innovation in the medical imaging domain.

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY

Advancing Diagnostic Imaging through Innovation
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0363-8715Frequency: 6 issues/year

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, published by Lippincott Williams & Wilkins, stands as a vital resource in the field of Radiology, Nuclear Medicine, and Imaging. Since its inception in 1977, this journal has been dedicated to advancing the understanding and application of computer-assisted tomography, emphasizing innovative research and clinical practices that enhance diagnostic imaging techniques. With an impact factor reflective of its rigorous scholarship and relevance—ranking in the Q3 category—the journal serves as an essential platform for contributors and readers alike, navigating the challenges and opportunities within a rapidly evolving field. Researchers, professionals, and students are encouraged to engage with the rich repository of articles that cover emerging technologies, clinical applications, and theoretical advancements, collectively fostering a deeper comprehension of imaging sciences. Although not currently designated as an open-access journal, it continues to enhance discourse in the community from its headquarters in Philadelphia, PA, maintaining a commitment to the highest standards of academic excellence.

Molecular Imaging and Radionuclide Therapy

Pioneering discoveries in the realm of nuclear medicine.
Publisher: GALENOS PUBL HOUSEISSN: 2146-1414Frequency: 3 issues/year

Molecular Imaging and Radionuclide Therapy is an esteemed academic journal published by GALENOS PUBL HOUSE, dedicated to advancing the fields of radiology, nuclear medicine, and imaging. Since its inception, this Open Access journal has facilitated the dissemination of high-quality research and innovative practices in molecular imaging and radionuclide therapy, making it a vital resource for researchers, professionals, and students alike. With an ISSN of 2146-1414 and an E-ISSN of 2147-1959, the journal has established its presence globally while specifically catering to the Turkish academic and medical community. As of 2023, it is ranked #241/333 in the Radiology, Nuclear Medicine and Imaging category on Scopus, holding a respectable Q3 quartile ranking. The journal serves as a platform for sharing impactful findings from 2017 to 2024, reinforcing its commitment to open access since 2011. With a dedication to enhancing the knowledge base in molecular imaging and therapy, it remains an important conduit for scholarly communication and collaborative research developments in this dynamic field.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Illuminating the Path of Molecular Imaging Discoveries
Publisher: SPRINGERISSN: 1619-7070Frequency: 12 issues/year

The European Journal of Nuclear Medicine and Molecular Imaging is a prestigious, peer-reviewed journal published by Springer, dedicated to advancing the field of nuclear medicine and molecular imaging. With an impressive impact factor and ranked in the Q1 category for both Medicine and Radiology, Nuclear Medicine and Imaging, this journal is a pivotal platform for researchers and practitioners to disseminate significant findings from 1996 to the present, reflecting the evolution of the field. The journal boasts a notable Scopus rank, standing at #8 out of 333 in its category, placing it in the top 3% of published works, which highlights its critical importance in shaping contemporary practices and research innovations. Although it does not offer an open-access model, the journal provides various access options to ensure that important research is accessible to professionals, students, and academics alike. Through rigorous peer review and a commitment to high-quality publication, the European Journal of Nuclear Medicine and Molecular Imaging plays an essential role in the advancement of nuclear medicine, contributing to better diagnostic and therapeutic outcomes globally.

American Journal of Nuclear Medicine and Molecular Imaging

Dedicated to the Evolution of Nuclear Medicine and Imaging Science
Publisher: E-CENTURY PUBLISHING CORPISSN: 2160-8407Frequency: 6 issues/year

The American Journal of Nuclear Medicine and Molecular Imaging (ISSN: 2160-8407), published by E-CENTURY PUBLISHING CORP, is a distinguished platform for the dissemination of cutting-edge research in the fields of nuclear medicine and molecular imaging. With a commitment to advancing scientific inquiry and clinical applications, this journal serves as a vital resource for researchers, clinicians, and students dedicated to exploring innovative imaging modalities, radiopharmaceuticals, and their applications in diagnosing and treating various medical conditions. Although currently not available as an open-access journal, this publication plays a crucial role in fostering academic dialogue and collaboration within the medical community. Its diverse range of topics and expert contributions underscore its impact in bridging the gap between research findings and clinical practice, making it an essential read for anyone interested in the rapidly evolving landscape of nuclear medicine and imaging technologies.

Revista Espanola de Medicina Nuclear e Imagen Molecular

Connecting Researchers to Transform Clinical Practices
Publisher: ELSEVIER ESPANA SLUISSN: 2253-654XFrequency: 6 issues/year

Revista Española de Medicina Nuclear e Imagen Molecular, published by Elsevier España SLU, stands as a vital resource in the field of Radiology, Nuclear Medicine, and Molecular Imaging. With an ISSN of 2253-654X, this journal is committed to disseminating high-quality research and advancements in clinical practices, aiming to bridge the gap between theoretical research and application in healthcare. Operating since 2012, it features a robust archive of peer-reviewed articles and case studies, although it currently holds a Q4 ranking in the Scopus category, indicating significant potential for growth and influence within the academic community. The journal is indexed in Scopus, with a rank of 255 out of 333, placing it in the 23rd percentile, which underlines the need for increased contributions from researchers eager to enhance its standing. While it is not an open-access journal, its availability through libraries and institutions ensures that a wide audience can access critical findings and innovations in the rapidly evolving field of nuclear medicine. As we look towards the convergence period from 2012 to 2024, Revista Española de Medicina Nuclear e Imagen Molecular aspires to fortify its role as a cornerstone for collaboration and advancement in nuclear imaging and radiology.

QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Connecting Researchers to Shape the Future of Imaging Science.
Publisher: EDIZIONI MINERVA MEDICAISSN: 1824-4785Frequency: 4 issues/year

The Quarterly Journal of Nuclear Medicine and Molecular Imaging, published by Edizioni Minerva Medica in Italy, serves as a pivotal platform for researchers and practitioners in the fields of Nuclear Medicine and Molecular Imaging. With an ISSN of 1824-4785 and an E-ISSN of 1827-1936, this journal boasts a respectable impact factor and is positioned in the Q3 quartile of the Radiology, Nuclear Medicine and Imaging category, based on the latest 2023 evaluations. As the journal continues to converge from its inception in 2004 to its anticipated expansions through 2024, it aims to disseminate high-quality, peer-reviewed articles that advance the frontier of imaging technologies and their applications in clinical practice. Researchers, professionals, and students are encouraged to contribute to its diverse scope, which encompasses innovative research, clinical findings, and reviews that encapsulate cutting-edge advancements in the field, highlighting its importance as an essential resource for knowledge and collaboration.

Current Radiopharmaceuticals

Pioneering insights in radiopharmaceutical research.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4710Frequency: 4 issues/year

Current Radiopharmaceuticals, published by Bentham Science Publishers Ltd, is an esteemed journal dedicated to advancing the field of radiopharmaceuticals. With an ISSN of 1874-4710 and an E-ISSN of 1874-4729, this journal has been a significant platform for researchers since its inception in 2009, and will continue to contribute to the literature until at least 2024. Current Radiopharmaceuticals is recognized for its impactful contributions, holding a record of Q3 in Pharmacology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023, illustrating its vital role in these domains. The journal aims to provide a comprehensive overview of the latest techniques, applications, and innovations within the field of radiopharmaceutical science, catering to a diverse audience of researchers, professionals, and students. Despite its significant contributions, the journal remains committed to enriching the academic community with high-quality, peer-reviewed articles that can be accessed worldwide, reflecting a dedication to open dialogue and knowledge dissemination in radiopharmaceutical research.

CLINICAL NUCLEAR MEDICINE

Exploring the Frontiers of Diagnostic and Therapeutic Nuclear Medicine
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0363-9762Frequency: 12 issues/year

CLINICAL NUCLEAR MEDICINE is a premier journal dedicated to the field of nuclear medicine, published by Lippincott Williams & Wilkins. With a history of excellence since its inception in 1978, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to deepen their understanding of this rapidly evolving discipline. The journal holds a commendable Q2 ranking in both Medicine (miscellaneous) and Radiology, Nuclear Medicine and Imaging, reflecting its significant impact on advancing clinical practices and research. While currently not offered as an open-access publication, CLINICAL NUCLEAR MEDICINE ensures rigorous peer review and high-quality publications, contributing to the broad dissemination of cutting-edge studies and reviews. With its comprehensive scope encompassing both diagnostic and therapeutic nuclear medicine applications, researchers around the globe turn to this journal to stay informed and inspire innovations in patient care for the years leading up to 2024 and beyond.

NUCLEAR MEDICINE REVIEW

Fostering Global Dialogue in Nuclear Medicine
Publisher: VIA MEDICAISSN: 1506-9680Frequency: 2 issues/year

NUCLEAR MEDICINE REVIEW is a distinguished journal in the field of radiology, nuclear medicine, and imaging, published by VIA MEDICA in Poland. Since its transition to an open access format in 1999, this journal has been dedicated to promoting the dissemination of knowledge and research findings across a global audience. With a focus on innovative approaches and advancements in nuclear medicine, it aims to serve as a key resource for researchers, professionals, and students who are working to further the understanding of nuclear imaging and its applications. In 2023, the journal was classified in the Q3 category within Radiology, Nuclear Medicine and Imaging, and Q4 in the broader category of Medicine (miscellaneous), highlighting its growing reputation in the academic community. As of the latest assessments, the journal has been ranked #235 out of 333 in its field according to Scopus metrics, reflecting its commitment to excellence and the relevance of its published works. The NUCLEAR MEDICINE REVIEW is a pivotal platform for those engaged in cutting-edge research, providing insights that drive the evolution of medical imaging and therapeutic techniques.